Beckman Coulter, the stylized logo and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. Not yet available for in vitro diagnostic use in the U.S. * CE Marked and is pending 510(k) clearance by the U.S. Automated hematology analyzer manufacturers' Instructions for Use (IFUs).ĭisclaimer: The Early Sepsis Indicator is not available in all countries.
DxH series side-by-side results documentation.Ģ. We share in our customers' mission toward continuous improvement and quality patient care because we believe when efficiency and clinical outcomes are improved, patients benefit and we can move healthcare forward for every person.ġ. Our scalable instruments, comprehensive diagnostic tests and business management services are trusted by hospitals, laboratories and other critical care settings around the world. For over 80 years, Beckman Coulter has been the partner of choice for healthcare organizations. These solutions provide a high level of continuity of care for clinical laboratories, regardless of whether they are small- or high-volume facilities.īeckman Coulter Diagnostics helps healthcare and laboratory professionals provide better patient care by delivering the accurate diagnostic information they need, when they need it. The DxH 900 hematology analyzer complements the recently announced DxH 520* system, and further expands Beckman Coulter's hematology portfolio. This test can be performed on the DxH 900 analyzer. Beckman Coulter is evaluating a hematology sepsis* parameter that is part of a routinely ordered test in the emergency department, where earlier recognition and treatment of sepsis can begin.
A recognized global healthcare concern, sepsis puts patients in grave danger and places a significant burden on the healthcare system as a whole. Sepsis, is another often-deadly condition that affects millions of people worldwide each year.
Many of the parameters available with the DxH 900 analyzer are designed to directly impact patient care by addressing critical conditions, such as thrombocytopenia, anemia and leukopenia. 2 Further, the DxH 900 features one of the smallest footprints in its class, making it highly efficient in utilization of laboratory space. Adding to this is the analyzer's lean reagent portfolio, which includes four reagents compared to 11 reagents required by other analyzers. This helps to generate reportable results as quickly as possible, reducing the time, supplies and costs that may be required for systems with higher repeat rates. The DxH 900 analyzer demonstrates industry-leading 93% first-pass throughput, 1 providing accurate flagging and reducing the number of slide reviews. At the same time, the system includes automated solutions that streamline the number of procedural steps needed to produce those results, offering predictable performance and greater laboratory efficiency."
"The suite of technologies is intended to help laboratories deliver quality results for fast, accurate clinical decision-making. Truly, the DxH 900 was designed by customers for customers," said Peter Soltani, Ph.D., senior vice president and general manager of the hematology business at Beckman Coulter. We had over 100 of our customers view prototypes, and we enhanced our designs based on their input. "The DxH 900 hematology analyzer is an example of our commitment to the voice of the customer. These features offer high-resolution analysis of cells in their near-native states, providing a precise cellular assessment for excellent red blood cell, platelet and white blood cell test results on the first pass.
Foundational to the system are its core technologies, including the enhanced Coulter Principle, VCS 360 and DataFusion. The DxH 900 analyzer offers advanced technologies to support patient care, by delivering the right results the first time. The DxH 900 is now available for sale in Europe, the United States, Canada, Australia and New Zealand. System helps laboratories deliver fast, accurate results through near native-state cellular characterization, precise flagging and a 93% first-pass throughput 1īREA, California, /PRNewswire/ - Beckman Coulter announced today the release of the DxH 900 hematology analyzer, giving mid- to high-volume clinical laboratories the ability to perform complete blood count and white blood cell differential tests with minimal repeats.